Harry An Email and Phone Number

Expert in nucleosides and related compounds as well as drug discovery and developmentMulti-year pharmaceutical/biotech industry experiences in drug discovery and development settings; discovered numerous leads, pushed leads to clinical studies; proven experimental, research, and managerial skills with outstanding scientific record of publications and patent inventions. Accomplishment Brief Received his Ph. D. degree in synthetic organic chemistry at Brigham Young University, and completed his postdoctoral training at the University of Virginia.  Has over 20 years of pharmaceutical experience at Ionis, Acea, and Valeant with a broad experience in medicinal, synthetic organic, combinatorial, and nucleoside chemistry.  His teams developed combinatorial technology and established the largest nucleoside library.  Has been working on hit generation, hit-to-lead, and optimization for antiviral and anticancer drug discovery by targeting kinase, microtubule, RdRp, RT, proteasome and others.  Successfully pushed lead compounds from scratch to clinics for HIV, HCV, HBV, kinase and antimitotic drugs; Lead full range of anticancer and antiviral drug development up to IND approval.  Authored or co-authored over 60 publications in leading journals, and co-invented over 40 patents.